PubMed Health⌕ Search

Biomedical subjects

Ries Kranse

Publications and source records attributed to Ries Kranse.

14 recordsLinked to original sources
PubMed2006

Metastatic disease of screen-detected prostate cancer : characteristics at diagnosis.

BACKGROUND: Screening for prostate cancer has not only led to a stage migration, but also to a higher incidence of the disease. A decrease in mortality has occurred in several countries during the same time period. Risk stratification of screen-detected cancers at diagnosis has become more important for the anticipation and interpretation of changing incidence/mortality ratios. METHODS: From 1993 to 1998, 633 men were diagnosed with nonmetastatic prostate cancer in the prevalence screen of the Rotterdam section of the European Randomized study of Screening for Prostate Cancer (ERSPC). The characteristics at diagnosis of men who developed metastatic disease were compared with men without evidence of metastases during follow-up. RESULTS: During the median follow-up of 7.5 years, 41 men developed metastatic disease. After 10 years the metastasis-free survival rate was 89.6%, the overall survival 64.7%. In a Cox-model 2logPSA (prostate-specific antigen), biopsy Gleason score and the number of biopsy cores with prostate cancer were independent predictors for the development of metastases; the latter only predicted metastases that presented within 60 months of follow-up. CONCLUSIONS: The metastasis-free survival of men with prostate cancer detected in a prevalence screening was very high. Whether this was related to the beneficial effects of screening or to overdiagnosis due to screening (or both) remains unclear. The prognostic factors known for clinically diagnosed disease also hold for screen-detected disease.

Aged↗
PubMed2006

Should we replace the Gleason score with the amount of high-grade prostate cancer?

OBJECTIVES: The stage and grade shift of currently diagnosed prostate cancer has led to a diminished prognostic power of the Gleason score system. We investigated the predictive value of the amount of high-grade cancer (Gleason growth patterns 4/5) in the biopsy for prostate-specific antigen (PSA) and clinical relapse after radical prostatectomy. METHODS: PSA-tested participants (N=281) of the European Randomized Study of Screening for Prostate Cancer (ERSPC) who underwent radical prostatectomy were analyzed. Besides clinical features, and serum-PSA, histopathologic features as determined in the diagnostic biopsy and matching radical prostatectomy specimen were related to patient outcome. RESULTS: At a median follow-up of 7 yr, 39 (13.9%), 24 (8.5%), and 12 (4.3%) patients had PSA >/=0.1 ng/ml, PSA >/=1.0 ng/ml, and clinical relapse after radical prostatectomy, respectively. Using Cox proportional hazards, PSA level (p=0.002), length of tumour (p=0.040), and length of high-grade cancer (p=0.006) in the biopsy, but not Gleason score, were independent prognostic factors for biochemical relapse (PSA >/=0.1 ng/ml) when assessed as continuous variables. In radical prostatectomies, the proportion of high-grade cancer (p<0.001) was most predictive of relapse (PSA >/=0.1 ng/ml). For PSA >/=1.0 ng/ml and clinical relapse, the amount of high-grade cancer, both in the biopsy specimen (p=0.016 and p=0.004, respectively) and radical prostatectomy specimen (p=0.002 and p=0.005, respectively), but not Gleason score, was an independent predictor. CONCLUSIONS: In biopsy and radical prostatectomy specimens of surgically treated prostate cancer, the amount of high-grade cancer is superior to the Gleason grading system in predicting patient outcome. We propose that, in addition to the Gleason score, the amount of Gleason growth patterns 4/5 in the biopsy (whether absolute length or proportion) should be mentioned in the pathology report.

Aged↗
PubMed2006

A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam).

BACKGROUND: The identification of predictors for prostate biopsy outcome at two screening rounds using a PSA>or=3.0 ng/ml as biopsy indication. MATERIALS AND METHODS: We compared predictors by means of descriptive statistics and logistic regression analysis in men (55-75 years) biopsied in either the 1st or 2nd screening round of ERSPC Rotterdam (interval 4 years). RESULTS: Positive predictors for biopsy outcome in both screening rounds were an increased PSA level in the absence of a previous negative biopsy (PrevNB), DRE and TRUS suspicious and a positive family history (PFH). A higher than median prostate volume was a consistent negative predictor. Having had a PrevNB at initial screening strongly reduced the chance of cancer detection at repeat screening and in addition canceled the predictive potential of PSA. CONCLUSION: If "detecting prostate cancer efficiently" were the aim, this study indicates that a "PSA only based biopsy threshold" may be replaced by another criterion incorporating, e.g., DRE, TRUS and prostate volume in men who were biopsied in the preceding 4 year interval.

Aged↗
PubMed2006

Does PSA velocity predict prostate cancer in pre-screened populations?

UNLABELLED: PSA-driven screening has been applied to a large part of the male population in many countries. An elevated PSA in secondary screens may indicate benign enlargement of the prostate rather than prostate cancer. In such cases the yearly rate of increase of PSA (PSA velocity [PSAV]) may improve the test characteristics of PSA. MATERIALS AND METHODS: Data from the European Randomized Study of Screening for Prostate Cancer Rotterdam are used to study the issue. Relative sensitivity, relative specificity, and positive predictive value (PPV) are calculated. Logistic regression analysis is used to compare odds ratios for positive biopsies. The relationship between PSAV and parameters of tumour aggressiveness is investigated. RESULTS: Five hundred eighty-eight consecutive participants were identified who presented at their first screening with PSA values <4.0 and who progressed to PSA values >4.0 ng/ml four years later. None were biopsied in round one, all were biopsied in round two. Relative sensitivity and specificity depend strongly on PSAV cut-offs of 0.25-1.0 ng/ml/yr. The use of PSAV cut-offs does not improve the PPV of the PSA cut-off of 4.0 ng/ml, nor do any of the PSAV cut-offs improve the odds ratio for identifying prostate cancer with respect to the cut-off value of 4.0 ng/ml. The rate of aggressive cancers seems to increase with increasing PSAV. CONCLUSIONS: PSAV does not improve the detection characteristics of a PSA cut-off of 4.0 ng/ml in secondary screening after four years.

Aged↗
PubMed2005

Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled study.

The objective of this study was to show or to exclude an effect of dietary supplement on rising prostate-specific antigen (PSA) levels. We have studied the effect of a dietary supplement (verum, administered for 6 weeks) containing plant estrogens, antioxidants, including carotenoids, selenium and other putative prostate cancer inhibiting substances in a randomized placebo-controlled double-blind crossover study in 37 hormonally untreated men with prostate cancer and increasing PSA levels. Outcome measures were changes in the rates of change of serum concentrations of total and free PSA and changes in male sex hormone levels. Male sex hormone levels were significantly lower during the verum phase (DHT: -0.11 nmol/L, p = 0.005; testosterone: -1 nmol/L, p = 0.02). Total PSA doubling time was unaffected. Free PSA, which increased during the placebo phase (average doubling time of 68 weeks), decreased during the verum period (average half-life of 13 weeks; p = 0.02). In those men in whom the free androgen index decreased (21 out of 32), a significant decrease in the slopes of both total and free PSA was observed (p = 0.04). Overall total PSA doubling times did not increase significantly during verum. However, the study demonstrates that this dietary intervention reduces DHT and testosterone levels and increases free PSA doubling time (and total PSA doubling time in a relevant subgroup). If future studies confirm that these observations translate into a slowing of disease progression, a dietary intervention may become an attractive option for prostate cancer treatment and prevention.

Aged↗
PubMed2004

Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policy.

PURPOSE: We evaluated prostate cancer (PCa) characteristics at diagnosis and changes in prostatic specific antigen (PSA) with time in males with screening detected PCa that was initially managed with a watchful waiting policy. MATERIALS AND METHODS: Patients with histologically proven PCa and PSA less than 10 ng/ml were selected from the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. The choice of initiating a watchful waiting policy was patient desire or physician advice. PSA slope and PSA doubling time (PSADT) were calculated in patients with 3 or more PSA tests results available. RESULTS: A total of 191 patients were included. Mean age at diagnosis was 69 years and mean PSA was 3.9 ng/ml. Of the patients 92.6% had a Gleason score of 3 + 3 or lower, 133 had a followup of greater than 12 months (mean 40) and 35 (29.2%) had a negative PSA slope. Mean PSADT was 9.7 years (range 0.3 to 155) in 85 males with a positive PSA slope. During followup 30 patients changed therapy. CONCLUSIONS: Watchful waiting remains a controversial prostate cancer treatment strategy. In select screening detected patients with PCa there appears to be a subgroup with stable or even decreasing PSA values with time. These males could profit from a watchful waiting policy with possible deferred treatment. Together with conventional tumor parameters at diagnosis PSADT and PSA slope during followup could be used to monitor tumor activity and possibly aid in determining the time of deferred treatment. Further followup is mandatory to validate these results.

Aged↗
PubMed2003

Causes for variability in repeated pressure-flow measurements.

OBJECTIVES: To study the causes for the variation between measurements, which is considerable, in maximal flow rate (Qmax) and the associated detrusor pressure (PdetQmax). Because of the central role of Qmax and PdetQmax in the diagnosis of bladder outlet obstruction, this is reason for concern. METHODS: Spectral analysis was carried out on two consecutive urodynamic measurements in 131 patients. The parameters for bladder outlet resistance and bladder contraction strength were determined, and difference plots were made to study the systematic variations. Logistic regression analysis was used to study whether the differences represent true changes of the function of the lower urinary tract. RESULTS: Signal components in the detrusor pressure and the flow rate signal with frequencies of 1 Hz or greater may be considered noise. Filtering out these frequencies changes the estimates of Qmax and PdetQmax, but not the between-measurement difference in them. Bladder contractility and bladder outlet resistance were systematically lower in the second measurement. Both the systematic and nonsystematic between-measurement variations were statistically significant predictors for postvoid residual urine volume. CONCLUSIONS: The nonsystematic between-measurement variability in Qmax and PdetQmax apparently reflects true variability in the physiologic state of the bladder outlet. It therefore does not discredit the pressure-flow study as the preferred method in the diagnosis of bladder outlet obstruction. Rather, the pressure-flow study is the only currently available method to study and quantify the apparent within-patient variability in bladder outlet resistance and bladder contractility.

Analysis of Variance↗
PubMed2003

Weak correlation between bladder outlet obstruction and probability to void to completion.

OBJECTIVES: To investigate the weak correlation between bladder outlet obstruction (BOO), as diagnosed using the provisional International Continence Society nomogram for the definition of BOO in men, and postvoid residual urine volume. METHODS: The relationship between voiding to completion and several indexes for bladder outlet resistance and bladder contractility was studied in 131 pressure flow studies in male patients using multivariate logistic regression analysis. RESULTS: The International Continence Society nomogram and the related BOO index weakly predict for postvoid residual urine volume (areas under the receiver operating characteristic curve 0.63 and 0.64, respectively). The BOO index primarily measures bladder outlet resistance. If the nomogram or BOO index is augmented with bladder contractility information, the postvoid residual urine volume can be predicted significantly better (eg, area under the receiver operating characteristic curve [0.89] for the combination of the BOO index and bladder contractility information). CONCLUSIONS: The weak correlation between BOO and postvoid residual urine volume is related to the fact that emptying the bladder to completion depends on bladder contractility, as well as bladder outlet resistance. It is possible to estimate the probability to void to completion quite accurately on the basis of bladder outlet resistance and bladder contractility. We named this probability "relative bladder outlet resistance." A high probability of a postvoid residual urine volume may be assumed to indicate "relative BOO." By its very nature, the correlation between "relative BOO" and postvoid residual urine volume is good.

Area Under Curve↗
PubMed2003

Bladder outlet resistance.

PURPOSE: We developed a method to objectively compare methods for the quantification of bladder outlet resistance. MATERIALS AND METHODS: We studied unselected voiding cystometries from 131 male patients. Several models proposed for bladder outlet resistance were fitted to the lowest monotonically increasing part (bottom) of the pressure flow plots. In conjunction with a parameter for bladder contractility, the model parameters were used as predictors of post-void residual greater than 20% of filled volume. RESULTS: The pressure decrease in relaxed bladder outlet was best described by a linear function of the flow rate. The flow rate independent and dependent parts of that function were statistically significant predictors for residual. However, they could be combined into 1 index that was as efficient as the 2 numbers separately in predicting residual. This index is the average pressure of the bottom of the pressure flow plot. CONCLUSIONS: We describe how different models for the quantification of bladder outlet resistance can be compared objectively on the basis of their ability to predict a significant post-void residual. Using this criterion in an unselected group of measurements, the average pressure of the bottom of the pressure flow plot performed best as an index for bladder outlet resistance quantification. It combines (or weights) 2 components (dependent and independent flow rates) without losing its power to predict post-void residual.

Humans↗
PubMed2002

Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.

Two large-scale randomized screening trials, the Prostate, Lung, Colorectal and Ovary (PLCO) cancer trial in the USA and the European Randomized Screening for Prostate Cancer (ERSPC) trial in Europe are currently under way, aimed at assessing whether screening reduces prostate cancer mortality. Up to the end of 1998, 102,691 men have been randomized to the intervention arm and 115,322 to the control arm (which represents 83% of the target sample size) from 7 European countries and 10 screening centers in the USA. The principal screening method at all centers is determination of serum prostate-specific antigen (PSA). The PLCO trial and some European centers use also digital rectal examination (DRE) as an ancillary screening test. In the core age group (55-69 years), 3,362 of 32,486 men screened (10%) had a serum PSA concentration of 4 ng/ml or greater, which is 1 cut-off for biopsy (performed in 84%). An additional 6% was referred for further assessment based on other criteria, with much less efficiency. Differences in PSA by country are largely attributable to the age structure of the study population. The mean age-specific PSA levels are lower in the PLCO trial (1.64 ng/ml [in the age group 55-59 years], 1.80 [60-64 years] and 2.18 [65-69 years) than in the ERSPC trial (1.28-1.71 [55-59], 1.75-2.87 [60-64] and 2.48-3.06 [65-69 years]). Detection rates at the first screen in the ERSPC trial range from 11 to 42/1,000 men screened and reflect underlying differences in incidence rates and screening procedures. In centers with consent to randomization design, adherence in the screening arm is 91%, but less than half of the men in the target population are enrolled in the trial. In population-based centers in which men were randomized prior to consent, all eligible subjects are enrolled, but only about two-thirds of the men in the intervention arm undergo screening. Considerable progress has been made in both trials. Enrollment will be completed in 2001. A substantial number of early prostate cancers have been detected. The differences between countries seem to reflect both underlying prostate cancer incidence and screening policy. The trials have the power to show definitive results in 2005-2008.

Aged↗
PubMed2002

A more advanced clinical stage is positively correlated with an increased prostate cancer detection rate.

OBJECTIVES: To determine whether an additional subclassification of the assessed clinical stage for prostate cancer before biopsy increases our ability to predict the biopsy outcome. A suspicious digital rectal examination (DRE) and/or a suspicious transrectal ultrasound (TRUS) investigation increases the likelihood of prostate cancer given a certain prostate-specific antigen level. METHODS: Biopsies done in 2199 men with suspicious DRE and/or TRUS findings were studied. The clinical stage was assessed according to the 1992 TNM classification. Univariate and multivariate statistical analyses were performed. RESULTS: The assessed extent of disease classified as intracapsular or extracapsular (ie, clinical Stage T2 versus T3 and T4) was a significant independent predictor for the biopsy outcome. Men with suspected extracapsular disease on the basis of the DRE findings before the sextant biopsy had a twofold increased odds ratio of having prostate cancer detected compared with men with suspected intracapsular disease. A suspicion of extracapsular disease on the basis of TRUS findings, however, significantly decreased the risk of having prostate cancer detected in a biopsy. CONCLUSIONS: We found a modified version of the clinical stage (ie, extracapsular, clinical T3 or T4 cancer versus intracapsular) to be significantly better in predicting the presence of prostate cancer at a given prostate-specific antigen level than a simple "yes or no abnormality found on DRE and/or TRUS" qualification. A suspicion of extracapsular disease raised on the basis of the DRE findings should be valued differently than a similar suspicion raised on the basis of the TRUS findings. Apparently, the extracapsular lesions seen by TRUS are primarily nonmalignant.

Aged↗
PubMed2002

Pre-selection of patients for pressure-flow analysis based on the maximum flow rate.

OBJECTIVE: To study the effects of the application of flow rate prescreening to select men for invasive pressure-flow studies, notably the reduction of invasive pressure-flow measurements that can be achieved and the proportion of men in whom, on the basis of the application of a prescreening, an invasive measurement is unjustly not indicated (false negatives). In addition, the variables on which these effects depend are studied. MATERIALS AND METHODS: Two hundred and sixty-two pressure-flow measurements in 131 patients (2 measurements/patient) and 89 free-flow measurements that preceded the invasive measurements in some patients were studied. A mathematical model was developed based on the outcomes of the invasive measurements. By means of the model the effects of several flow rate prescreening scenarios were estimated. A comparison of the model predicted and actually observed effects of flow rate prescreening was made for those measurements that were preceded by a free-flow rate measurement. RESULTS: The application of a free-flow rate prescreening may result in a reduction of the number of invasive measurements of 20-30% at a 5% false negative rate. The reduction that may be achieved at an assumed constant false negative rate depends on the distribution of the maximum flow rate in the population and on the definition of bladder outlet obstruction used. When the measurement selection procedure was applied to the free-flow rate measurements that were available in 89 patients, a 21% reduction in invasive measurement indications was found (25% expected). Four patients (4.5%) would have been unjustly excluded from invasive procedures (maximally 5% expected), three of these four patients were borderline obstructed. CONCLUSION: Considering the bother and risk to the patient and the cost of invasive measurements we think that a 20-30% gain in efficiency at a 5% risk of unjustly declaring a patient unobstructed makes a flow rate prescreening procedure cost effective in the diagnosis of bladder outlet obstruction.

Algorithms↗
PubMed2002

Relative bladder outlet obstruction.

PURPOSE: Currently bladder outlet obstruction in males is defined by the provisional International Continence Society nomogram which is partly based on expert opinion and partly on measurements before and after transurethral prostate resection. Recently there has been some interest in the development of a similar nomogram for females. MATERIALS AND METHODS: We studied the possibility of defining bladder outlet obstruction based on a sign that it causes, namely post-void residual urine. RESULTS: The probability of relative post-void residual urine exceeding 20% of bladder capacity was modeled in males and females using 1 parameter, that is URA/w20 or the ratio of the obstruction parameter urethral resistance factor (URA)-to-the bladder contractility parameter Watts factor at 20% (w20). URA/w20 represents relative bladder outlet resistance or bladder outlet resistance normalized to bladder contractility. Above a threshold of URA/w20 = 6.8 in females and 8.2 in males a relative post-void residual exceeding 20% was noted in 90% of measurements. These thresholds may be used to define relative obstruction. The provisional International Continence Society nomogram for obstruction in males was transformed into an identical nomogram for females by equating the probabilities of post-void residual urine in each gender. The latter differed from that in men, in that the lines demarcating the zones were horizontal or flow rate independent but the intercepts were approximately the same at 20 and 40 cm. water. CONCLUSIONS: Instead of defining obstruction as an absolute level of bladder outlet resistance we suggest that it is better to define it relatively, that is as a level of bladder outlet resistance that depends on bladder contractility.

Female↗